Divide And Conquer With Biomarkers: An Interview With Interleukin Genetics CEO Lewis Bender (Part 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Segmenting large markets using biomarkers is a logical “insurance policy” to help protect big bets in development. If only pharma companies would consider the idea outside oncology.